News coverage about Celcuity (NASDAQ:CELC) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Celcuity earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.0853919237639 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Separately, Craig Hallum began coverage on Celcuity in a report on Monday, October 16th. They issued a “buy” rating on the stock.

Shares of Celcuity (NASDAQ:CELC) traded up $1.52 during midday trading on Monday, hitting $21.35. The stock had a trading volume of 44,307 shares, compared to its average volume of 35,264. Celcuity has a 12-month low of $11.10 and a 12-month high of $19.84.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at

Celcuity Company Profile

Celcuity, Inc is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it.

Receive News & Ratings for Celcuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.